Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.

Nicholas J. Vogelzang,Andrew J. Armstrong,Celestia S. Higano,A. Oliver Sartor,Christopher Michael Pieczonka,Raoul S. Concepcion,Ronald F. Tutrone,Carl A. Olsson,James Bailen,David F. Penson,Nancy N. Chang,Jennifer Susan LIll,Robert C. Tyler,Matthew R. Cooperberg

Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.

2016

Nicholas J. Vogelzang
Andrew J. Armstrong
Celestia S. Higano
A. Oliver Sartor
Christopher Michael Pieczonka
Raoul S. Concepcion
Ronald F. Tutrone
Carl A. Olsson
James Bailen
David F. Penson
Nancy N. Chang
Jennifer Susan LIll
Robert C. Tyler
Matthew R. Cooperberg

e16503Background: Sipuleucel-T (sip-T) is an FDA-approved autologous cellular immunotherapy targeting prostatic acid phosphatase in select men with mCRPC. The phase 4 PROCEED (NCT01306890) registry...

Keywords:

Prostate cancer
Urology
Castration
Medicine
Autologous Cellular Immunotherapy
Oncology
castration resistant
Internal medicine
Prostatic acid phosphatase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations